Discuss iRhythm Technologies Inc
iRhythm Technologies Inc
WKN: A2ATTS / Symbol: IRTC / Name: iRhythm / Aktie / Ausrüstung & Versorgung / Small Cap /
62,00 €
-1,59 %
Sell iRhythm Technologies Inc
Sell iRhythm Technologies Inc
Buy iRhythm Technologies Inc
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Needham & Company LLC from $151.00 to $130.00. They now have a "buy" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $149.00 price target on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Truist Financial Co. from $155.00 to $138.00. They now have a "buy" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $110.00 price target on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Truist Financial Co. from $100.00 to $115.00. They now have a "buy" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Truist Financial Co. from $115.00 to $133.00. They now have a "buy" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Needham & Company LLC from $108.00 to $136.00. They now have a "buy" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Needham & Company LLC from $136.00 to $137.00. They now have a "buy" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at JPMorgan Chase & Co. from $142.00 to $133.00. They now have an "overweight" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target raised by analysts at Needham & Company LLC from $137.00 to $138.00. They now have a "buy" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $115.00 price target on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Morgan Stanley from $135.00 to $130.00. They now have an "overweight" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Needham & Company LLC from $138.00 to $119.00. They now have a "buy" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $117.00 price target on the stock, down previously from $134.00.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Robert W. Baird from $120.00 to $110.00. They now have an "outperform" rating on the stock.
Ratings data for IRTC provided by MarketBeat
iRhythm Technologies, Inc. (NASDAQ: IRTC) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $165.00 to $145.00. They now have an "outperform" rating on the stock.
Ratings data for IRTC provided by MarketBeat
I'm feeling pretty upbeat about iRhythm Technologies right now. They just reported some solid Q2 results that beat expectations, with 19.3% revenue growth year-over-year. That's nothing to sneeze at! The company seems to be gaining traction in its core markets and is pushing into primary care channels too. Plus, they're on track to launch in four European countries soon and are awaiting a regulatory decision in Japan later this year. Those could be big growth catalysts. The recent upgrade to a Zacks Rank #2 (Buy) is also encouraging. Sure, they're still posting losses, but they've got a hefty cash pile of over $560 million to fund growth. The stock has taken a hit this year, down about 19%, but that could present a buying opportunity if you believe in the long-term story. With strong momentum and multiple catalysts ahead, iRhythm looks well-positioned for future growth. Just keep in mind there are still risks, like potential regulatory hurdles or competition. But overall, I'm cautiously optimistic about iRhythm's prospects.
Neueste Beiträge
Jefferies_Financial_ in Baidu Inc. A ADR diskutieren